Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Plerixafor (Mozobil®) is recommended for use within NHS Wales in combination with granulocyte colony stimulating factor (G-CSF) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children aged ≥ 1 to <18 years with lymphoma or solid malignant tumours either:
|
|||
|
|||
Medicine details |
|||
| Medicine name | plerixafor (Mozobil®) | ||
| Formulation | 20 mg/ml solution for injection | ||
| Reference number | 3297 | ||
| Indication | In combination with granulocyte-colony stimulating factor (G-CSF) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children aged 1 to less than 18 years with lymphoma or solid malignant tumours, either: pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with G-CSF (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield; or who previously failed to collect sufficient haematopoietic stem cells |
||
| Company | Sanofi | ||
| BNF chapter | Nutrition & blood | ||
| Assessment type | Limited | ||
| Status | Recommended | ||
| Advice number | 0120 | ||
| NMG meeting date | 08/01/2020 | ||
| AWMSG meeting date | 11/02/2020 | ||
| Date of issue | 14/02/2020 | ||